RecruitingPhase 4NCT03781752
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
500 participants
Start Date
Mar 4, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Inclusion Criteria1
- \- Youth ages 6-17 years with ADHD as a primary diagnosis
Exclusion Criteria3
- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMethylphenidate
study to determine dose
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03781752
Related Trials
Trigeminal Nerve Stimulation for Children With Prenatal Alcohol Exposure
NCT068471651 location
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT0427840451 locations
Development of Virtual Reality-based Interventions to Strengthen Cognitive Skillsets Related to Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Phase I and Randomized Controlled Phase II Trial
NCT056084341 location
Fidgeting and Attentional and Emotional Regulation in ADHD
NCT045266001 location
Enhancing Team Effectiveness for a Collaborative School-based Intervention for ADHD
NCT061806811 location